Invention Grant
- Patent Title: Compounds that inhibit MCL-1 protein
-
Application No.: US17075864Application Date: 2020-10-21
-
Publication No.: US11685747B2Publication Date: 2023-06-27
- Inventor: Nick A. Paras
- Applicant: AMGEN INC.
- Applicant Address: US CA Thousand Oaks
- Assignee: AMGEN INC.
- Current Assignee: AMGEN INC.
- Current Assignee Address: US CA Thousand Oaks
- Agent Kimberly L. Berkowski
- Main IPC: C07C311/11
- IPC: C07C311/11 ; C07D513/10 ; C07D513/08 ; C07D498/00 ; C07C59/68 ; C07C59/56

Abstract:
Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I,
and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
Public/Granted literature
- US20210040120A1 COMPOUNDS THAT INHIBIT MCL-1 PROTEIN Public/Granted day:2021-02-11
Information query